Search the Newsreel

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Legend Biotech Corporation (NASDAQ:LEGN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $55.29. While the company reported a 56.5% year-over-year revenue increase to $305.1 million, it missed EPS estimates with an adjusted loss of $0.03 per …

Purple Biotech (NASDAQ: PPBT) posts Q2 2026 profit on warrant revaluation

Purple Biotech's IM1240 Shows ~8-Fold Longer Half-Life in Preclinical Data

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (bsADC) program into the next development stage after successfully completing the discovery phase with OmniAb Inc. The company will now focus on engineering the final therapeutic candidate and conducting preclinical validation. VERAXA also …

SANA Q1 2026 Earnings: Narrower-than-Expected Loss Points to Cost Discipline - Profit Growth Outlook

SANA Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 1.73% EPS Surprise - Segment Revenue Breakdown

PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71% - Change of Character

PPBT Q1 2025 Earnings: Pre-Revenue Biotech Posts $0.17 Per Share Loss as Pipeline Development Continues - Debt Analysis Report

EDSA Q2 2026 Earnings: Wider Loss and 84.77% Negative Surprise Spotlight Pre-Revenue R&D Outlays - Earnings Stability Report

NAUT Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.11 Per Share Beats Estimates

Jyong Biotech (MENS) Edges Up to $2.03, Holding a Tight Range Between Support and Resistance - Jelly Roll Trade

Jyong Biotech (MENS) Edges Higher to $2.03 as Range-Bound Trading Persists - Triple EMA

PDSB Q1 2026 Earnings: Narrower-than-Expected Loss Lifts Shares - Full Year Guidance

Concord Biotech Q1 FY27 revenue rises 26% to ₹257 crore on API strength

Hangzhou Diagens Biotechnology Announces Unaudited Interim Results for First Half of 2026

Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Puma Biotechnology, Inc. announced its financial results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in revenue to USD 56.5 million and net income rose to USD 8.19 million. However, for the …

PUMA BIOTECHNOLOGY, INC. 2026: Revenue $56.5M, EPS $0.16— 10-Q Summary

PUMA BIOTECHNOLOGY, INC. reported strong quarterly results for 2026, with revenue reaching $56.5 million and diluted EPS of $0.16, demonstrating significant year-over-year growth. Revenue growth was driven by increased volume in core product lines and a shift towards e-commerce, while operational improvements helped streamline …

Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

Oncolytics Biotech (ONCY) is scheduled to release its Q2 2026 earnings after market close on Friday, August 14th, with analysts forecasting a loss of $0.0538 per share. The company previously missed consensus estimates, reporting a $0.08-per-share loss. ONCY shares opened at $0.80, and the …

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology Inc. (PBYI) reported strong Q2 2026 results, becoming debt-free and raising its full-year revenue and net income guidance. The company saw significant growth in NERLYNX sales and is advancing its alisertib clinical program, planning for new Phase III trials in 2027. Despite …

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns

Puma Biotechnology (PBYI) exceeded Q2 2026 revenue and earnings estimates, reporting $56.5 million in revenue and $0.16 GAAP EPS, driven by strong NERLYNX sales. The company returned to profitability after a prior quarter loss and raised its full-year 2026 guidance for net product revenue …

CollPlant Biotechnologies Bolsters Authorized Share Capital and Validates Resale Shares After July Private Placement

Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants

A Schedule 13G filing indicates that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively hold a beneficial ownership of 4.99% in Moleculin Biotech, Inc. (MBRX), amounting to 973,927 shares. This ownership includes shares held directly by Intracoastal and shares issuable upon …

CollPlant Biotechnologies (CLGN) lifts share capital, files new resale opinion

CollPlant Biotechnologies (CLGN) reported that its shareholders approved an increase in authorized share capital from 30 million to 500 million ordinary shares, each with a par value of NIS 1.50. Following this approval, the company filed an updated legal opinion concerning the validity of …

Concord Biotech Limited Just Beat Revenue Estimates By 5.0%

Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants

Moleculin Biotech, Inc.'s CFO, Jonathan P. Foster, recently purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering. These were acquired at a combined price of $0.75 per unit, with each unit comprising one share and three warrants. Following …

California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS

The California State Teachers Retirement System increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.2% in the first quarter, now holding 26,186 shares valued at $6.76 million. Krystal Biotech reported strong Q1 earnings per share of $1.79, beating analyst estimates, although revenue slightly …

Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants

Moleculin Biotech, Inc.'s CEO, Walter V. Klemp, reported acquiring 533,333 shares of common stock and 1,599,999 Series I warrants in a public offering on August 3, 2026. The purchase was made at a combined price of $0.75 per common share and three accompanying warrants. …

Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap As ADC Pipeline News Builds?

Vir Biotechnology (VIR) Could Be 58% Below Fair Value On Q2 Profit Turnaround

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This comes after its Class A ordinary shares closed at or above $1.00 for 10 consecutive business days from July 20 to …

ZYBT Stock Whipsaws As Speculative Trading Frenzy Unwinds

Zhengye Biotechnology Holding Limited (ZYBT) stock experienced extreme volatility, whipsawing significantly due to speculative trading. After a massive 1,047% surge, the stock plunged by over 70% and continued to show significant premarket swings, indicating a classic boom-and-bust pattern driven by momentum rather than fundamentals. …

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology reported its second-quarter 2026 financial results, highlighting strong progress in its clinical programs for chronic hepatitis delta (CHD) and solid tumors. Key updates include promising Phase 2 SOLSTICE data for elebsiran and tobevibart in CHD, with Phase 3 ECLIPSE 1 trial data …

Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028

Earnings Call Insights: Vir Biotechnology (VIR) Q2 2026 MANAGEMENT VIEW * Dr. Marianne De Backer (President, CEO & Director) said Vir is “entering a catalyst-rich period for hepatitis delta,” after completing enrollment in ECLIPSE 2 and finishing enrollment “across all 3 registrational ECLIPSE studies,” …

Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.33, Implies 134% Upside

The average 12-month price target for Vir Biotechnology, Inc. (VIR) stock has been lowered by analysts from $21.56 to $21.11, with individual forecasts ranging from $16 to $30 per share. This updated target suggests a potential upside of approximately 132% based on the August …

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 5, 2026

Puma Biotechnology, Inc. announced the grant of inducement restricted stock unit awards covering 35,375 shares of common stock to five new non-executive employees on August 3, 2026. These awards, granted under the company's 2017 Employment Inducement Incentive Award Plan, vest over a three-year period …